The UAB NF Program is internationally recognized for its contributions to outstanding clinical care, research, and education related to all forms of neurofibromatosis (NF1, NF2, and schwannomatosis). We are the national coordinating center for the NF Clinical Trials Consortium, funded by the Department of Defense to perform clinical trials for all forms of neurofibromatsis.
Fixing cystic fibrosis: In vitro studies show therapeutically robust correction of the most common CF gene mutationIn experiments with isolated cystic fibrosis lung cells, University of Alabama at Birmingham researchers and colleagues from two other institutions have partially restored the lost function of those cells.
The work is proof-of-concept for using a yeast genetic model to find therapeutic targets, in this case for people with the most common cystic fibrosis mutation, called ∆F508-CFTR. This mutation affects close to 90 percent of patients with cystic fibrosis, and half of those have two copies of the mutation. Read more ...
Clinical Services: Our goal is to deliver outstanding care for patients and families through integrated clinical and laboratory services. For some conditions, we are considered a national and international referral source.
Research: We seek to expand knowledge and create new applications through laboratory and clinical research along the continuum from fundamental studies to preclinical investigations, to bench-to bedside translation, to clinical practice and community implementation.